Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy
The nomogram models established in this research provide an exceptionally accurate and individualized method for predicting recurrence and RFS in initially uHCC patients undergoing LPI-based conversion hepatectomy, potentially aiding clinicians in devising tailored treatment plans and enhancing patient outcomes.
Authors
- Danxi Liu (ORCID: https://orcid.org/0009-0006-6387-5324)
- Qingqing Pang
- Bin Huang (ORCID: https://orcid.org/0000-0003-4602-1782)
- Feixiang Wu (ORCID: https://orcid.org/0000-0001-6868-2181)
- Xiao‐Dong Mo (ORCID: https://orcid.org/0000-0002-9881-7945)
- Meng Wei (ORCID: https://orcid.org/0000-0002-6004-6401)
- Cheng Xu (ORCID: https://orcid.org/0000-0002-6019-6207)
- Zhihong Tang
Institutions
- Guangxi Medical University (CN)
- Tumor Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1602327
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
- Guangxi Medical University